Condition
SGA
Turner Syndrome
Noonan Syndrome
ISS
Locations
Not recruiting
Start date
01/02/2023
Identifiers
Trial ID
NN8640-4469,
NCT number NCT05723835,
Eudract number 2022-501055-87
NCT number NCT05723835,
Eudract number 2022-501055-87
Summary
The purpose of this study is to find out if somapacitan is safe and how well somapacitan works in children either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Somapacitan is a new growth hormone medicine for treatment of low level of growth hormone. The study will last for about 3 years. During the study, the participants will be treated with somapacitan once a week. Somapacitan can be injected anytime during the day. The study doctor or nurse will show how to inject somapacitan, so that the participant knows how to do it at home.
Trial Overview:
Treatment
DRUG: Somapacitan
Study type
INTERVENTIONAL
Trial duration
Feb 01 2023 - Oct 29 2027
Participants
48
Phase
III
Are you eligible?
Gender
Male and female
Age
10 to 18 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.